SynCon Zika DNA vaccine: Phase I start

Inovio and GeneOne said they plan to start “in the next weeks” an open-label Phase I trial to evaluate 1 or 2 mg DNA per intradermal dose of GLS-5700 in about 40 healthy volunteers. The companies are ...